ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Early onset colorectal cancer (EOCRC) among individuals under age 50 is increasing globally. While lifestyle factors such as obesity, metabolic comorbid conditions, poor diet, and sedentary behaviours are linked to EOCRC, critical gaps remain in identifying additional risk factors, with growing evidence in early-life and gut microbial-related exposures. In addition, how or when the risk factors act, individually or collectively, to initiate or promote CRC at much younger ages remains unknown. Compounding the complexity are the unique challenges of developing and implementing effective prevention strategies among younger populations. In this Roadmap, I review the progress and challenges of risk factor discovery for EOCRC, highlight opportunities for prevention, and propose a transdisciplinary framework integrating population, mechanistic, behavioural, and implementation sciences to accelerate causal risk factor discovery and translate insights into strategies to reverse the rising EOCRC burden. While currently implemented by Project MEPROT, this framework is broadly adaptable and intended to inspire collaborative efforts across the field. I also emphasize the critical role of patient perspectives and public engagement in shaping these efforts. With the urgency in risk factor discovery, scientists, the public, and policymakers must unite to transform knowledge into life-saving solutions for future generations.
Jovanovic I. 2026. Project MEPROT: Shaping the Future of Early Onset Colorectal Cancer Prevention. PREPRINTS.RU. https://doi.org/10.24108/preprints-3114629
1. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74, 229-263, doi:10.3322/caac.21834 (2024).
2. Sung, H. et al. Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol 26, 51-63, doi:10.1016/S1470-2045(24)00600-4 (2025).
3. Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974-2013. J Natl Cancer Inst 109, doi:10.1093/jnci/djw322 (2017).
4. Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut 68, 2179-2185, doi:10.1136/gutjnl-2019-319511 (2019).
5. Howren, A. et al. Trends in the Incidence of Young onset Colorectal Cancer With a Focus on Years Approaching Screening Age: A Population-Based Longitudinal Study. J Natl Cancer Inst 113, 863-868, doi:10.1093/jnci/djaa220 (2021).
6. Chambers, A. C. et al. Demographic trends in the incidence of young onset colorectal cancer: a population-based study. Br J Surg 107, 595-605, doi:10.1002/bjs.11486 (2020).
7. Gerrard, A. D. et al. The Increased Early Onset Colorectal Cancer in South East Scotland Is Indicative of a Wider UK Problem. Cancers (Basel) 17, doi:10.3390/cancers17121913 (2025).
8. Araghi, M. et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol 4, 511-518, doi:10.1016/S2468-1253(19)30147-5 (2019).
9. Sinicrope, F. A. Increasing Incidence of Early onset Colorectal Cancer. N Engl J Med 386, 1547-1558, doi:10.1056/NEJMra2200869 (2022).
10. Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H. & Boland, C. R. The rising tide of early onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol 7, 262-274, doi:10.1016/S2468-1253(21)00426-X (2022).
11. Cercek, A. et al. A Comprehensive Comparison of Early onset and Average onset Colorectal Cancers. J Natl Cancer Inst 113, 1683-1692, doi:10.1093/jnci/djab124 (2021).
12. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J Clin 73, 17-48, doi:10.3322/caac.21763 (2023).
13. Nors, J., Gotschalck, K. A., Erichsen, R. & Andersen, C. L. Risk of recurrence in early onset versus late onset non-metastatic colorectal cancer, 2004-2019: a nationwide cohort study. Lancet Reg Health Eur 47, 101093, doi:10.1016/j.lanepe.2024.101093 (2024).
14. Demb, J. et al. Red Flag Signs and Symptoms for Patients With Early onset Colorectal Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open 7, e2413157, doi:10.1001/jamanetworkopen.2024.13157 (2024).
15. Gryfe, R. et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342, 69-77, doi:10.1056/NEJM200001133420201 (2000).
16. Akimoto, N. et al. Rising incidence of early onset colorectal cancer - a call to action. Nat Rev Clin Oncol 18, 230-243, doi:10.1038/s41571-020-00445-1 (2021).
17. Silver, A. et al. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer 130, 1082-1092, doi:10.1002/ijc.26104 (2012).
18. Li, J. et al. Patterns in genomic mutations among patients with early onset colorectal cancer: an international, multicohort, observational study. Lancet Oncol, doi:10.1016/s1470-2045(25)00239-6 (2025).
19. Jin, Z. et al. Clinicopathological and Molecular Characteristics of Early onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. J Natl Cancer Inst 113, 1693-1704, doi:10.1093/jnci/djab123 (2021).
20. Willauer, A. N. et al. Clinical and molecular characterization of early onset colorectal cancer. Cancer 125, 2002-2010, doi:10.1002/cncr.31994 (2019).
21. Alsop, K. et al. Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years. Eur J Cancer 42, 1357-1361, doi:10.1016/j.ejca.2006.02.023 (2006).
22. Liu, P. H. et al. Association of Obesity With Risk of Early onset Colorectal Cancer Among Women. JAMA Oncol 5, 37-44, doi:10.1001/jamaoncol.2018.4280 (2019).
23. O'Sullivan, D. E. et al. Risk Factors for Early onset Colorectal Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 20, 1229-1240 e1225, doi:10.1016/j.cgh.2021.01.037 (2022).
24. Chen, H. et al. Metabolic syndrome, metabolic comorbid conditions and risk of early onset colorectal cancer. Gut 70, 1147-1154, doi:10.1136/gutjnl-2020-321661 (2021).
25. Khoa Ta, H. D. et al. Association of diabetes mellitus with early onset colorectal cancer: A systematic review and meta-analysis of 19 studies including 10 million individuals and 30,000 events. Diabetes Metab Syndr 17, 102828, doi:10.1016/j.dsx.2023.102828 (2023).
26. Li, Z. et al. Type 2 Diabetes and Risk of Early onset Colorectal Cancer. Gastro Hep Adv 1, 186-193, doi:10.1016/j.gastha.2021.10.009 (2022).
27. Schumacher, A. J., Chen, Q., Attaluri, V., McLemore, E. C. & Chao, C. R. Metabolic Risk Factors Associated with Early onset Colorectal Adenocarcinoma: A Case-Control Study at Kaiser Permanente Southern California. Cancer Epidemiol Biomarkers Prev 30, 1792-1798, doi:10.1158/1055-9965.Epi-20-1127 (2021).
28. Du, M., Drew, D. A., Goncalves, M. D., Cao, Y. & Chan, A. T. Early onset colorectal cancer as an emerging disease of metabolic dysregulation. Nat Rev Endocrinol 21, 686-702, doi:10.1038/s41574-025-01159-z (2025).
29. Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early onset Colorectal Cancer. J Natl Cancer Inst 113, 543-552, doi:10.1093/jnci/djaa164 (2021).
30. Nguyen, L. H. et al. The Sulfur Microbial Diet Is Associated With Increased Risk of Early onset Colorectal Cancer Precursors. Gastroenterology 161, 1423-1432.e1424, doi:10.1053/j.gastro.2021.07.008 (2021).
31. Hur, J. et al. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early onset colorectal cancer among women. Gut 70, 2330-2336, doi:10.1136/gutjnl-2020-323450 (2021).
32. Jin, E. H. et al. Sex and Tumor-Site Differences in the Association of Alcohol Intake With the Risk of Early onset Colorectal Cancer. J Clin Oncol 41, 3816-3825, doi:10.1200/jco.22.01895 (2023).
33. Nguyen, L. H. et al. Sedentary Behaviors, TV Viewing Time, and Risk of Young onset Colorectal Cancer. JNCI Cancer Spectr 2, pky073, doi:10.1093/jncics/pky073 (2018).
34. Sung, H. et al. Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data. Lancet Public Health 9, e583-e593, doi:10.1016/s2468-2667(24)00156-7 (2024).
35. Mohammad Mirzaei, N., Hur, C., Terry, M. B., Dalerba, P. & Yang, W. Modeling Early onset Cancer Kinetics Reveals Changes in Underlying Risk and the Impact of Population Screening. Cancer Res 85, 4558-4570, doi:10.1158/0008-5472.Can-25-0186 (2025).
36. Wang, C. et al. Ultraprocessed Food Consumption and Risk of Early onset Colorectal Cancer Precursors Among Women. JAMA Oncol, doi:10.1001/jamaoncol.2025.4777 (2025).
37. Qin, Y. et al. Consistent signatures in the human gut microbiome of old- and young onset colorectal cancer. Nat Commun 15, 3396, doi:10.1038/s41467-024-47523-x (2024).
38. Asnicar, F. et al. Gut micro-organisms associated with health, nutrition and dietary interventions. Nature, doi:10.1038/s41586-025-09854-7 (2025).
39. Zhou, Z. et al. Beneficial microbiome and diet interplay in early onset colorectal cancer. EMBO Mol Med 17, 9-30, doi:10.1038/s44321-024-00177-0 (2025).
40. Richter, K. M. et al. Model systems to study tumor-microbiome interactions in early onset colorectal cancer. EMBO Mol Med 17, 395-413, doi:10.1038/s44321-025-00198-3 (2025).
41. Díaz-Gay, M. et al. Geographic and age variations in mutational processes in colorectal cancer. Nature 643, 230-240, doi:10.1038/s41586-025-09025-8 (2025).
42. Peng, T. & Zhan, Q. Single-cell integration analysis reveals molecular signatures of the tumor microenvironment in early onset colorectal cancer. NPJ Precis Oncol 9, 360, doi:10.1038/s41698-025-01129-8 (2025).
43. GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050. Lancet 404, 2278-2298, doi:10.1016/S0140-6736(24)01548-4 (2024).
44. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027-1050, doi:10.1016/S0140-6736(23)02750-2 (2024).
45. Song, J. H. et al. Association of changes in obesity and abdominal obesity status with early onset colorectal cancer risk: a nationwide population-based cohort study. Front Med (Lausanne) 10, 1208489, doi:10.3389/fmed.2023.1208489 (2023).
46. Murphy, C. C. et al. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer. Gut 71, 1332-1339, doi:10.1136/gutjnl-2021-325001 (2022).
47. Samuelsson, A. M. et al. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of developmental programming. Hypertension 51, 383-392, doi:10.1161/hypertensionaha.107.101477 (2008).
48. Fullston, T. et al. Paternal obesity initiates metabolic disturbances in two generations of mice with incomplete penetrance to the F2 generation and alters the transcriptional profile of testis and sperm microRNA content. Faseb j 27, 4226-4243, doi:10.1096/fj.12-224048 (2013).
49. CDC. National Diabetes Statistics Report. (2024).
50. Misra, S. et al. Current insights and emerging trends in early onset type 2 diabetes. Lancet Diabetes Endocrinol 11, 768-782, doi:10.1016/S2213-8587(23)00225-5 (2023).
51. McHenry, S. et al. Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. Hepatol Commun 6, 3299-3310, doi:10.1002/hep4.2073 (2022).
52. Kim, S. et al. Association Between Nonalcoholic Fatty Liver Disease and Risk of Early onset Colorectal Cancer. Clin Gastroenterol Hepatol, doi:10.1016/j.cgh.2025.02.020 (2025).
53. Wang, D. D. et al. Trends in dietary quality among adults in the United States, 1999 through 2010. JAMA Intern Med 174, 1587-1595, doi:10.1001/jamainternmed.2014.3422 (2014).
54. Liu, J., Rehm, C. D., Onopa, J. & Mozaffarian, D. Trends in Diet Quality Among Youth in the United States, 1999-2016. Jama 323, 1161-1174, doi:10.1001/jama.2020.0878 (2020).
55. Petimar, J. et al. Recommendation-based dietary indexes and risk of colorectal cancer in the Nurses' Health Study and Health Professionals Follow-up Study. Am J Clin Nutr 108, 1092-1103, doi:10.1093/ajcn/nqy171 (2018).
56. Park, S. Y., Boushey, C. J., Wilkens, L. R., Haiman, C. A. & Le Marchand, L. High-Quality Diets Associate With Reduced Risk of Colorectal Cancer: Analyses of Diet Quality Indexes in the Multiethnic Cohort. Gastroenterology 153, 386-394.e382, doi:10.1053/j.gastro.2017.04.004 (2017).
57. Archambault, A. N. et al. Nongenetic Determinants of Risk for Early onset Colorectal Cancer. JNCI Cancer Spectr 5, doi:10.1093/jncics/pkab029 (2021).
58. Yue, Y. et al. Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women. Ann Oncol 32, 778-786, doi:10.1016/j.annonc.2021.03.200 (2021).
59. Nielsen, S. J. & Popkin, B. M. Changes in beverage intake between 1977 and 2001. Am J Prev Med 27, 205-210, doi:10.1016/j.amepre.2004.05.005 (2004).
60. Goncalves, M. D. et al. High-fructose corn syrup enhances intestinal tumor growth in mice. Science 363, 1345-1349, doi:doi:10.1126/science.aat8515 (2019).
61. Taylor, S. R. et al. Dietary fructose improves intestinal cell survival and nutrient absorption. Nature 597, 263-267, doi:10.1038/s41586-021-03827-2 (2021).
62. Berry, K. A., Choquette, E. M., Looby, A. & Rancourt, D. Unification of the food and alcohol disturbance literature: A systematic review. Clin Psychol Rev 113, 102486, doi:10.1016/j.cpr.2024.102486 (2024).
63. Shi, M. et al. Alcohol Drinking Without Meals Is Associated With Risk of Gastrointestinal Cancers, Including Early onset Cases. Gastroenterology 166, 341-344 e345, doi:10.1053/j.gastro.2023.11.012 (2024).
64. Wang, L. et al. Trends in Consumption of Ultraprocessed Foods Among US Youths Aged 2-19 Years, 1999-2018. Jama 326, 519-530, doi:10.1001/jama.2021.10238 (2021).
65. Ravandi, B. et al. Prevalence of processed foods in major US grocery stores. Nat Food 6, 296-308, doi:10.1038/s43016-024-01095-7 (2025).
66. Fortin, B. M. et al. The diverse roles of the circadian clock in cancer. Nat Cancer 6, 753-767, doi:10.1038/s43018-025-00981-8 (2025).
67. Sanz, Y. et al. The gut microbiome connects nutrition and human health. Nat Rev Gastroenterol Hepatol, doi:10.1038/s41575-025-01077-5 (2025).
68. Guthold, R., Stevens, G. A., Riley, L. M. & Bull, F. C. Global trends in insufficient physical activity among adolescents: a pooled analysis of 298 population-based surveys with 1·6 million participants. Lancet Child Adolesc Health 4, 23-35, doi:10.1016/s2352-4642(19)30323-2 (2020).
69. Yang, L. et al. Trends in Sedentary Behavior Among the US Population, 2001-2016. Jama 321, 1587-1597, doi:10.1001/jama.2019.3636 (2019).
70. Bressa, C. et al. Differences in gut microbiota profile between women with active lifestyle and sedentary women. PLoS One 12, e0171352, doi:10.1371/journal.pone.0171352 (2017).
71. Kerr, J., Anderson, C. & Lippman, S. M. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol 18, e457-e471, doi:10.1016/s1470-2045(17)30411-4 (2017).
72. Pinto, A. J. et al. Physiology of sedentary behavior. Physiol Rev 103, 2561-2622, doi:10.1152/physrev.00022.2022 (2023).
73. Nagengast, F. M., Grubben, M. J. & van Munster, I. P. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 31a, 1067-1070, doi:10.1016/0959-8049(95)00216-6 (1995).
74. Beale, M. N. et al. Physical Activity and Stool Metabolite Relationships Among Adults at High Risk for Colorectal Cancer. J Phys Act Health 18, 1404-1411, doi:10.1123/jpah.2020-0876 (2021).
75. Zepeda-Rivera, M. et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature 628, 424-432, doi:10.1038/s41586-024-07182-w (2024).
76. Piccinno, G. et al. Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer. Nat Med, doi:10.1038/s41591-025-03693-9 (2025).
77. Sonnenburg, E. D. & Sonnenburg, J. L. The ancestral and industrialized gut microbiota and implications for human health. Nat Rev Microbiol 17, 383-390, doi:10.1038/s41579-019-0191-8 (2019).
78. Lu, S. S. M. et al. Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study. J Natl Cancer Inst 114, 38-46, doi:10.1093/jnci/djab125 (2022).
79. Cao, Y. et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut 67, 672-678, doi:10.1136/gutjnl-2016-313413 (2018).
80. Murphy, C. C. et al. In-utero exposure to antibiotics and risk of colorectal cancer in a prospective cohort of 18 000 adult offspring. Int J Epidemiol 52, 1448-1458, doi:10.1093/ije/dyad004 (2023).
81. Nguyen, L. H. et al. Antibiotic Therapy and Risk of Early onset Colorectal Cancer: A National Case-Control Study. Clin Transl Gastroenterol 13, e00437, doi:10.14309/ctg.0000000000000437 (2022).
82. Kane, K. J. et al. Oral Antibiotic Use in Adulthood and Risk of Early onset Colorectal Cancer: A Case-Control Study. Clin Gastroenterol Hepatol, doi:10.1016/j.cgh.2024.09.002 (2024).
83. Wampach, L. et al. Birth mode is associated with earliest strain-conferred gut microbiome functions and immunostimulatory potential. Nat Commun 9, 5091, doi:10.1038/s41467-018-07631-x (2018).
84. Shao, Y. et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 574, 117-121, doi:10.1038/s41586-019-1560-1 (2019).
85. Cao, Y. et al. Evaluation of Birth by Cesarean Delivery and Development of Early onset Colorectal Cancer. JAMA Netw Open 6, e2310316, doi:10.1001/jamanetworkopen.2023.10316 (2023).
86. Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nature Reviews Immunology 16, 626-638, doi:10.1038/nri.2016.90 (2016).
87. Wilson, M. R. et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 363, doi:10.1126/science.aar7785 (2019).
88. Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123, doi:10.1126/science.1224820 (2012).
89. Arthur, J. C. et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun 5, 4724, doi:10.1038/ncomms5724 (2014).
90. Kim, H. et al. Total Vitamin D Intake and Risks of Early onset Colorectal Cancer and Precursors. Gastroenterology 161, 1208-1217 e1209, doi:10.1053/j.gastro.2021.07.002 (2021).
91. Kim, Y. et al. Serum 25-Hydroxyvitamin D Levels and Risk of Colorectal Cancer: An Age-Stratified Analysis. Gastroenterology 165, 920-931, doi:10.1053/j.gastro.2023.06.029 (2023).
92. Low, E. E. et al. Risk Factors for Early onset Colorectal Cancer. Gastroenterology 159, 492-501 e497, doi:10.1053/j.gastro.2020.01.004 (2020).
93. Pritchett, N. et al. Exposure to Outdoor Particulate Matter Air Pollution and Risk of Gastrointestinal Cancers in Adults: A Systematic Review and Meta-Analysis of Epidemiologic Evidence. Environ Health Perspect 130, 36001, doi:10.1289/ehp9620 (2022).
94. Li, X. et al. Colonic Injuries Induced by Inhalational Exposure to Particulate-Matter Air Pollution. Adv Sci (Weinh) 6, 1900180, doi:10.1002/advs.201900180 (2019).
95. Li, S., Keenan, J. I., Shaw, I. C. & Frizelle, F. A. Could Microplastics Be a Driver for Early Onset Colorectal Cancer? Cancers (Basel) 15, doi:10.3390/cancers15133323 (2023).
96. Saad, M. F. S. et al. Exploring the role of Bisphenol A in obesity-driven colorectal cancer progression: network toxicology and multi-organ pathology in animal models. Toxicol Appl Pharmacol 495, 117227, doi:10.1016/j.taap.2025.117227 (2025).
97. Wild, C. P. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 14, 1847-1850, doi:10.1158/1055-9965.EPI-05-0456 (2005).
98. Wild, C. P. The exposome: from concept to utility. Int J Epidemiol 41, 24-32, doi:10.1093/ije/dyr236 (2012).
99. Hofseth, L. J. et al. Early onset colorectal cancer: initial clues and current views. Nat Rev Gastroenterol Hepatol 17, 352-364, doi:10.1038/s41575-019-0253-4 (2020).
100. Shi, M. et al. Circulating markers of microbial translocation and host response to bacteria with risk of colorectal cancer: a prospective, nested case-control study in men. EBioMedicine 91, 104566, doi:10.1016/j.ebiom.2023.104566 (2023).
101. Silpe, J. E. & Balskus, E. P. Deciphering Human Microbiota-Host Chemical Interactions. ACS Cent Sci 7, 20-29, doi:10.1021/acscentsci.0c01030 (2021).
102. Constantinides, M. G. et al. MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science 366, doi:10.1126/science.aax6624 (2019).
103. Klibaner-Schiff, E. et al. Environmental exposures influence multigenerational epigenetic transmission. Clin Epigenetics 16, 145, doi:10.1186/s13148-024-01762-3 (2024).
104. Mauri, G., Patelli, G., Crisafulli, G., Siena, S. & Bardelli, A. Tumor "age" in early onset colorectal cancer. Cell 188, 589-593, doi:10.1016/j.cell.2024.12.003 (2025).
105. Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA Cancer J Clin 73, 233-254, doi:10.3322/caac.21772 (2023).
106. Fritz, C. D. L. et al. Red-flag signs and symptoms for earlier diagnosis of early onset colorectal cancer. J Natl Cancer Inst 115, 909-916, doi:10.1093/jnci/djad068 (2023).
107. Ganguli, I. et al. Declining use of primary care among commercially insured adults in the United States, 2008–2016. Annals of internal medicine 172, 240-247 (2020).
108. Lamprell, K. et al. People with early onset colorectal cancer describe primary care barriers to timely diagnosis: a mixed-methods study of web-based patient reports in the United Kingdom, Australia and New Zealand. BMC Prim Care 24, 12, doi:10.1186/s12875-023-01967-0 (2023).
109. AlZaabi, A. et al. Early onset colorectal cancer: Challenges across the cancer care continuum. Ann Med Surg (Lond) 82, 104453, doi:10.1016/j.amsu.2022.104453 (2022).
110. Vitaloni, M. et al. Clinical challenges and patient experiences in early onset colorectal cancer: insights from seven European countries. BMC Gastroenterol 25, 378, doi:10.1186/s12876-025-03976-y (2025).
111. Zhang, L. et al. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. Nat Med 29, 1135-1145, doi:10.1038/s41591-023-02315-6 (2023).
112. U. S. Preventive Services Task Force et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965-1977, doi:10.1001/jama.2021.6238 (2021).
113. Liu, P. H., Sanford, N. N., Liang, P. S., Singal, A. G. & Murphy, C. C. Persistent Disparities in Colorectal Cancer Screening: A Tell-Tale Sign for Implementing New Guidelines in Younger Adults. Cancer Epidemiol Biomarkers Prev 31, 1701-1709, doi:10.1158/1055-9965.Epi-21-1330 (2022).
114. Ying, X., Yao, L., Mathis, W. S., Congly, S. E. & Jesudian, A. B. Geographic Disparities in Access to Gastroenterologists in the United States. Gastroenterology 168, 1189-1191.e1181, doi:10.1053/j.gastro.2025.01.232 (2025).
115. Rex, D. K. et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153, 307-323, doi:10.1053/j.gastro.2017.05.013 (2017).
116. Ladabaum, U., Mannalithara, A., Meester, R. G. S., Gupta, S. & Schoen, R. E. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years. Gastroenterology 157, 137-148, doi:10.1053/j.gastro.2019.03.023 (2019).
117. Carethers, J. M. Stool-Based Screening Tests for Colorectal Cancer. Jama 329, 839-840, doi:10.1001/jama.2023.0547 (2023).
118. Imperiale, T. F. et al. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med 390, 984-993, doi:10.1056/NEJMoa2310336 (2024).
119. Barnell, E. K. et al. Multitarget Stool RNA Test for Colorectal Cancer Screening. Jama 330, 1760-1768, doi:10.1001/jama.2023.22231 (2023).
120. Chung, D. C. et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med 390, 973-983, doi:10.1056/NEJMoa2304714 (2024).
121. Shaukat, A. et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. Jama, doi:10.1001/jama.2025.7515 (2025).
122. Mon, H. M., Robb, K. A. & Demou, E. Effectiveness of workplace cancer screening interventions: a systematic review. BMC Cancer 24, 999, doi:10.1186/s12885-024-12649-0 (2024).
123. Chan, A. T. & Giovannucci, E. L. Primary prevention of colorectal cancer. Gastroenterology 138, 2029-2043.e2010, doi:10.1053/j.gastro.2010.01.057 (2010).
124. Beresford, S. A. et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. Jama 295, 643-654, doi:10.1001/jama.295.6.643 (2006).
125. Hull, M. A. Nutritional prevention of colorectal cancer. Proc Nutr Soc 80, 59-64, doi:10.1017/s0029665120000051 (2021).
126. Drew, D. A., Cao, Y. & Chan, A. T. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16, 173-186, doi:10.1038/nrc.2016.4 (2016).
127. Katona, B. W. & Weiss, J. M. Chemoprevention of Colorectal Cancer. Gastroenterology 158, 368-388, doi:10.1053/j.gastro.2019.06.047 (2020).
128. Wang, L., Wang, W., Kaelber, D. C., Xu, R. & Berger, N. A. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA Oncol 10, 256-258, doi:10.1001/jamaoncol.2023.5573 (2024).
129. Suzuki, Y. et al. Association of SGLT2 inhibitors with incident cancer. Diabetes Metab 50, 101585, doi:10.1016/j.diabet.2024.101585 (2024).
130. Finn, O. J. The dawn of vaccines for cancer prevention. Nat Rev Immunol 18, 183-194, doi:10.1038/nri.2017.140 (2018).
131. Kimura, T. et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6, 18-26, doi:10.1158/1940-6207.Capr-12-0275 (2013).
132. Ferrer, R. A. et al. Relationships among health perceptions vary depending on stage of readiness for colorectal cancer screening. Health Psychol 30, 525-535, doi:10.1037/a0023583 (2011).
133. Weinstein, N. D. & Sandman, P. M. in Health behavior and health education: Theory, research, and practice (eds K. Glanz, B.K. Rimer, & F.M. Lewis) 121-143 (John Wiley and Sons, 2002).
134. Dougherty, M. K. et al. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med 178, 1645-1658, doi:10.1001/jamainternmed.2018.4637 (2018).
135. Hay, J. L., Orom, H., Kiviniemi, M. T. & Waters, E. A. "I don't know" my cancer risk: exploring deficits in cancer knowledge and information-seeking skills to explain an often-overlooked participant response. Med Decis Making 35, 436-445, doi:10.1177/0272989x15572827 (2015).
136. Sanders Thompson, V. L., Ackermann, N., Bauer, K. L., Bowen, D. J. & Goodman, M. S. Strategies of community engagement in research: definitions and classifications. Transl Behav Med 11, 441-451, doi:10.1093/tbm/ibaa042 (2021).
137. Rana, T., Chan, D. N. S., Nguyen, K. T., Choi, K. C. & So, W. K. W. Effectiveness of Community Health Worker-Led Interventions in Enhancing Colorectal Cancer Screening Uptake in Racial and Ethnic Minority Populations: A Systematic Review and Meta-analysis. Cancer Nurs 47, 368-376, doi:10.1097/ncc.0000000000001222 (2024).
138. Noar, S. M., Benac, C. N. & Harris, M. S. Does tailoring matter? Meta-analytic review of tailored print health behavior change interventions. Psychol Bull 133, 673-693, doi:10.1037/0033-2909.133.4.673 (2007).
139. Hull, M. A., Rees, C. J., Sharp, L. & Koo, S. A risk-stratified approach to colorectal cancer prevention and diagnosis. Nat Rev Gastroenterol Hepatol 17, 773-780, doi:10.1038/s41575-020-00368-3 (2020).
140. Usher-Smith, J. A., Walter, F. M., Emery, J. D., Win, A. K. & Griffin, S. J. Risk Prediction Models for Colorectal Cancer: A Systematic Review. Cancer Prev Res (Phila) 9, 13-26, doi:10.1158/1940-6207.Capr-15-0274 (2016).
141. Smith, T. et al. Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies. Gut 68, 672-683, doi:10.1136/gutjnl-2017-315730 (2019).
142. Waters, E. A. et al. Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success. Cancer Epidemiol Biomarkers Prev 29, 2389-2394, doi:10.1158/1055-9965.Epi-20-0861 (2020).
143. Waters, E. A., Foust, J. L., Scherer, L. D., McQueen, A. & Taber, J. M. Adherence of Internet-Based Cancer Risk Assessment Tools to Best Practices in Risk Communication: Content Analysis. J Med Internet Res 23, e23318 (2021).
144. Weinstein, N. D. et al. Colon cancer: risk perceptions and risk communication. J Health Commun 9, 53-65, doi:10.1080/10810730490271647 (2004).
145. McCloud, R. F., Kohler, R. E. & Viswanath, K. Cancer Risk-Promoting Information: The Communication Environment of Young Adults. Am J Prev Med 53, S63-s72, doi:10.1016/j.amepre.2017.03.025 (2017).
146. Sarkar, U. et al. Using Social Media to Target Cancer Prevention in Young Adults: Viewpoint. J Med Internet Res 20, e203, doi:10.2196/jmir.8882 (2018).
147. French, D. P., Cameron, E., Benton, J. S., Deaton, C. & Harvie, M. Can Communicating Personalised Disease Risk Promote Healthy Behaviour Change? A Systematic Review of Systematic Reviews. Ann Behav Med 51, 718-729, doi:10.1007/s12160-017-9895-z (2017).
148. Soloe, C. et al. Factors that support readiness to implement integrated evidence-based practice to increase cancer screening. Implement Sci Commun 3, 106, doi:10.1186/s43058-022-00347-6 (2022).
149. Rutters, F. et al. Lifestyle interventions for cardiometabolic health. Nat Med 30, 3455-3467, doi:10.1038/s41591-024-03373-0 (2024).
150. Tsipa, A. et al. Promoting colorectal cancer screening: a systematic review and meta-analysis of randomised controlled trials of interventions to increase uptake. Health Psychol Rev 15, 371-394, doi:10.1080/17437199.2020.1760726 (2021).
151. Seguin, R. A. et al. Strong Hearts, healthy communities: a rural community-based cardiovascular disease prevention program. BMC Public Health 16, 86, doi:10.1186/s12889-016-2751-4 (2016).
152. Aiyegbusi, O. L. et al. Considerations for patient and public involvement and engagement in health research. Nature Medicine 29, 1922-1929, doi:10.1038/s41591-023-02445-x (2023).
153. Manochakian, R. & Dizon, D. S. Using social media for patient-driven cancer research. Nature Reviews Cancer 23, 1-2, doi:10.1038/s41568-022-00528-4 (2023).
154. Pandya, T., Cao, Y., Smith-Byrne, K. & Swanton, C. Mechanism-Enhanced Population Science: Strengthening Population Studies Through Mechanistic Insights. Ann Oncol, doi:10.1016/j.annonc.2025.08.006 (2025).
155. Stancliffe, E. et al. An Untargeted Metabolomics Workflow that Scales to Thousands of Samples for Population-Based Studies. Anal Chem 94, 17370-17378, doi:10.1021/acs.analchem.2c01270 (2022).
156. Sebastiani, P. et al. Metabolite signatures of chronological age, aging, survival, and longevity. Cell Rep 43, 114913, doi:10.1016/j.celrep.2024.114913 (2024).
157. Valles-Colomer, M. et al. The person-to-person transmission landscape of the gut and oral microbiomes. Nature 614, 125-135, doi:10.1038/s41586-022-05620-1 (2023).
158. Wacker, S. A., Houghtaling, B. R., Elemento, O. & Kapoor, T. M. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat Chem Biol 8, 235-237, doi:10.1038/nchembio.779 (2012).
159. Jost, M. & Weissman, J. S. CRISPR Approaches to Small Molecule Target Identification. ACS Chem Biol 13, 366-375, doi:10.1021/acschembio.7b00965 (2018).
160. Zha, L., Wilson, M. R., Brotherton, C. A. & Balskus, E. P. Characterization of Polyketide Synthase Machinery from the pks Island Facilitates Isolation of a Candidate Precolibactin. ACS Chem Biol 11, 1287-1295, doi:10.1021/acschembio.6b00014 (2016).
161. Brotherton, C. A., Wilson, M., Byrd, G. & Balskus, E. P. Isolation of a metabolite from the pks island provides insights into colibactin biosynthesis and activity. Org Lett 17, 1545-1548, doi:10.1021/acs.orglett.5b00432 (2015).
162. Jiang, Y. et al. Reactivity of an Unusual Amidase May Explain Colibactin's DNA Cross-Linking Activity. J Am Chem Soc 141, 11489-11496, doi:10.1021/jacs.9b02453 (2019).
163. Martin, E. M. & Fry, R. C. Environmental Influences on the Epigenome: Exposure- Associated DNA Methylation in Human Populations. Annu Rev Public Health 39, 309-333, doi:10.1146/annurev-publhealth-040617-014629 (2018).
164. Ma, S. et al. Chromatin Potential Identified by Shared Single-Cell Profiling of RNA and Chromatin. Cell 183, 1103-1116.e1120, doi:10.1016/j.cell.2020.09.056 (2020).
165. El Tekle, G. & Garrett, W. S. Bacteria in cancer initiation, promotion and progression. Nat Rev Cancer 23, 600-618, doi:10.1038/s41568-023-00594-2 (2023).
166. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov 12, 31-46, doi:10.1158/2159-8290.Cd-21-1059 (2022).
167. Liu, Y. et al. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Am J Clin Nutr 118, 614-626, doi:10.1016/j.ajcnut.2023.04.017 (2023).
168. Grade Study Research Group et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 387, 1063-1074, doi:10.1056/NEJMoa2200433 (2022).
169. Wolff Sagy, Y. et al. Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study. EClinicalMedicine 83, 103213, doi:10.1016/j.eclinm.2025.103213 (2025).
170. Bushi, G. et al. Association Between GLP1 RAs Use and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis. Health Sci Rep 8, e70490, doi:10.1002/hsr2.70490 (2025).
171. Gardner, I. H. et al. A Distinct Innate Immune Signature of Early Onset Colorectal Cancer. Immunohorizons 5, 489-499, doi:10.4049/immunohorizons.2000092 (2021).
172. Yang, Y. et al. Dysbiosis of human gut microbiome in young onset colorectal cancer. Nat Commun 12, 6757, doi:10.1038/s41467-021-27112-y (2021).
173. Zhang, F. et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience 24, 103382, doi:10.1016/j.isci.2021.103382 (2021).
174. Gao, H. et al. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. Biol Pharm Bull 38, 694-702, doi:10.1248/bpb.b14-00505 (2015).
175. Madsen, M. S. A. et al. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep 9, 15582, doi:10.1038/s41598-019-52103-x (2019).
176. Yang, Z. et al. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front Pharmacol 13, 925377, doi:10.3389/fphar.2022.925377 (2022).
177. Wang, J. & Kim, C. H. Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. Endocr Res 47, 18-25, doi:10.1080/07435800.2021.1955255 (2022).
178. Aune, D. et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 343, d6617, doi:10.1136/bmj.d6617 (2011).
179. Thakur, B. K. et al. Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer. Nat Microbiol 10, 855-870, doi:10.1038/s41564-025-01938-4 (2025).
180. Carroll, K. L., Fruge, A. D., Heslin, M. J., Lipke, E. A. & Greene, M. W. Diet as a Risk Factor for Early onset Colorectal Adenoma and Carcinoma: A Systematic Review. Front Nutr 9, 896330, doi:10.3389/fnut.2022.896330 (2022).
181. Scheelbeek, P. et al. Health impacts and environmental footprints of diets that meet the Eatwell Guide recommendations: analyses of multiple UK studies. BMJ Open 10, e037554, doi:10.1136/bmjopen-2020-037554 (2020).
182. Filho, A. M. et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer 156, 1336-1346, doi:10.1002/ijc.35278 (2025).
183. Directorate of Health. Colorectal cancer screening, <https://island.is/en/colorectal-cancer-screening> (
184. Health New Zealand. National Bowel Screening Programme,, <https://info.health.nz/keeping-healthy/cancer-screening/bowel-screening> (
185. Folkehelseinstituttet. Tarmscreeningprogrammet, <https://www.fhi.no/kreft/kreftscreening/tarmscreening/> (
186. Dutta, A., Pratiti, R., Kalantary, A., Aboulian, A. & Shekherdimian, S. Colorectal Cancer: A Systematic Review of the Current Situation and Screening in North and Central Asian Countries. Cureus 15, e33424, doi:10.7759/cureus.33424 (2023).
187. Irazola, V. et al. Quality improvement intervention to increase colorectal cancer screening at the primary care setting: a cluster-randomised controlled trial. BMJ Open Qual 12, doi:10.1136/bmjoq-2022-002158 (2023).
